Phenylketonuria (PKU)
Conditions
Brief summary
The 165-901 study is designed to identify the appropriate tools for use in future interventional studies on the neurocognitive effects of pegvaliase on adults with PKU.
Detailed description
Clinical studies have suggested that treatment with pegvaliase results in lowering of blood Phenylalanine levels in adults with Phenylketonuria (PKU). Because these individuals often exhibit inattention and mood difficulties, and blood Phe concentration affects cognition and mood, life-long blood Phe control with pegvaliase may improve cognitive abilities and emotional and mental health in patients with PKU. In order to adequately quantify potential pegvaliase treatment impact on cognition and mood, it is necessary to employ clinical outcome assessments (COAs) that are fit for purpose and that comprehensively address concepts important, relevant, and meaningful to PKU patients. This is an observational study to identify symptom, function, and health-related quality of life (HRQoL) concepts of interest (COIs) to patients with PKU and to seek additional patient, observer, and expert input on the appropriateness of concepts of BioMarin's proposed COAs for use in future efficacy trials in PKU.
Interventions
None listed
Sponsors
BioMarin Pharmaceutical
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Patients eligible to participate in this study must meet all of the following criteria: 1. ≥18 and ≤70 years of age at the time of consent; 2. Clinically-confirmed diagnosis of Phenylketonuria (PKU); 3. Blood Phe test completed within eight weeks prior to screening date or blood Phe test completed within eight weeks post screening date; 4. Able to read, understand, and speak fluently the language(s) of their designated country sufficiently to participate in an interview and/or complete all assessments; 5. Willing and able to participate in a telephone interview lasting approximately 90 minutes; 6. Willing to be audio-recorded during the interview session; 7. Willing and able to provide written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate.
Exclusion criteria
Patients meeting any of the following criteria will not be included in the study: 1. Currently pregnant; 2. Current or previous exposure to pegvaliase treatment or participation in a pegvaliase clinical trial; 3. Has a significant cognitive impairment, hearing difficulty, visual impairment, acute psychopathology, medical condition, or insufficient knowledge of the interview language that, in the opinion of the investigator or interviewer, would interfere with his or her ability to provide written consent and participate/complete an interview.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PKU Symptom Survey | 15 minutes | 60 item survey asking patients, observers and clinical experts about the symptoms and behaviors associated with PKU and changes in Phe level. |
Countries
Canada, France, Germany, Italy, Turkey (Türkiye), United Kingdom, United States
Outcome results
None listed